Highly efficient derivation of ventricular cardiomyocytes from induced pluripotent stem cells with a distinct epigenetic signature.
about
Programming and reprogramming a human heart cellCellular reprogramming: a small molecule perspectiveInduced pluripotent stem cell-derived cardiac progenitors differentiate to cardiomyocytes and form biosynthetic tissuesReprogramming with Small Molecules instead of Exogenous Transcription FactorsInhibition of stearoyl-coA desaturase selectively eliminates tumorigenic Nanog-positive cells: improving the safety of iPS cell transplantation to myocardiumDifferentiation of spontaneously contracting cardiomyocytes from non-virally reprogrammed human amniotic fluid stem cells.Action potential morphology of human induced pluripotent stem cell-derived cardiomyocytes does not predict cardiac chamber specificity and is dependent on cell densityIn vitro differentiation and expansion of human pluripotent stem cell-derived pancreatic progenitors.Reprogramming for cardiac regeneration.The current status of iPS cells in cardiac research and their potential for tissue engineering and regenerative medicine.Epigenomic Reprogramming of Adult Cardiomyocyte-Derived Cardiac Progenitor CellsCD166(pos) subpopulation from differentiated human ES and iPS cells support repair of acute lung injury.Human pluripotent stem cell-derived cardiomyocytes for heart regeneration, drug discovery and disease modeling: from the genetic, epigenetic, and tissue modeling perspectives.Reprogramming-derived gene cocktail increases cardiomyocyte proliferation for heart regeneration.Epigenetic state network approach for describing cell phenotypic transitions.The case for induced pluripotent stem cell-derived cardiomyocytes in pharmacological screening.Prospective in vitro models of channelopathies and cardiomyopathiesEpithelial to mesenchymal transition as a portal to stem cell characters embedded in gene networks.Regenerative medicine for the treatment of heart disease.Recent advances in heart regeneration.Advancements in Induced Pluripotent Stem Cell Technology for Cardiac Regenerative Medicine.On the road to bioartificial organs.Perspectives of induced pluripotent stem cells for cardiovascular system regeneration.Differentiation of Cardiomyocytes from Human Pluripotent Stem Cells Using Monolayer Culture.Establishment of human cell type-specific iPS cells with enhanced chondrogenic potential.Human iPSC-derived cardiomyocytes and tissue engineering strategies for disease modeling and drug screening.Cord blood cell-derived iPSCs as a new candidate for chondrogenic differentiation and cartilage regeneration.Generation of new cardiomyocytes after injury: de novo formation from resident progenitors vs. replication of pre-existing cardiomyocytes.Selection via pluripotency-related transcriptional screen minimizes the influence of somatic origin on iPSC differentiation propensity.The 2013 special issue on stem cell biology.Comparative study of human-induced pluripotent stem cells derived from bone marrow cells, hair keratinocytes, and skin fibroblasts.Chondrogenic Pellet Formation from Cord Blood-derived Induced Pluripotent Stem Cells.
P2860
Q26823933-9E5AA0A6-F23A-4AB2-A959-3C0B97D6D913Q26829509-92EFDE89-3DAD-4099-BD02-0FA5A14A2FD6Q27315974-D65C6587-F804-454D-9AA1-DE1F95E0D8EFQ28084394-65FB46FF-8111-48F9-9F77-6465620E657DQ28305306-B02128CC-2B86-40F0-AC99-634A681F79B0Q33699342-2FC4CCB0-2B4D-41ED-ABF7-C584DA49B29BQ34862866-8CEE6180-F4E0-4C1C-8E2D-4878250FB50EQ34972307-892C5B15-F0C6-45D1-B839-E499301AEC48Q35156623-B28D79C3-E0A2-4344-A4BC-9287E92F8D5AQ35765543-F0819A96-E58A-4D01-840C-9C174D5F2D11Q36367191-B7BA5D94-74AB-462D-8F4E-9A1A9240982AQ36460474-D90C52BD-6D66-4C66-95C0-53963BFA62CEQ37372183-568A9BA1-2066-44B0-8C24-FCAEBAF9904DQ37617991-8350A4EC-7E72-4F98-9B93-2001BB277945Q37718336-9175BEA2-ABF1-4448-A22D-46FCCBCD803BQ38030589-B0F60F73-0E49-470B-B426-A216F50C6400Q38042625-F9E9EC11-2C25-4343-A64E-A5CF61716255Q38044317-39A2EC3C-D3F9-4CB4-A093-A4FFD5AE0FF6Q38075104-51BF3CFA-8396-4466-A0E8-6D6E7337FF45Q38147034-D8128164-2BE3-47C3-BD4C-7E91DB93661AQ38197882-E46A1185-DA1C-4571-AE12-D1D3257397CAQ38201281-E13B6F58-19A6-465E-8191-C9AEAFA0D725Q38321098-A274710C-CA64-42D0-89EC-401296C30B6FQ38519835-7DD8377F-D148-47CF-941A-357AD2366FC0Q38981862-B69C5636-0304-4EE1-B72C-77ED7C55A131Q39050993-9F2C0523-0C77-4D35-94E8-62C3B6DC13FCQ40361510-BF88BEA1-0C4E-4E21-8E7C-C8E445975181Q40859404-714EAE24-F8AA-4662-B844-BFB2AD14E0B4Q42146807-62A5A672-C232-4ACC-B92D-6F76E7E7675BQ42637606-3EB39117-4AB0-49B7-A2BB-A1DDD0D1DA21Q44608716-2414D06A-3408-450F-B364-F54A3384E9FAQ50168335-B54A0F91-9866-4BBD-9989-B132FD1AF0EC
P2860
Highly efficient derivation of ventricular cardiomyocytes from induced pluripotent stem cells with a distinct epigenetic signature.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Highly efficient derivation of ...... distinct epigenetic signature.
@ast
Highly efficient derivation of ...... distinct epigenetic signature.
@en
type
label
Highly efficient derivation of ...... distinct epigenetic signature.
@ast
Highly efficient derivation of ...... distinct epigenetic signature.
@en
altLabel
Highly efficient derivation of ...... distinct epigenetic signature
@en
prefLabel
Highly efficient derivation of ...... distinct epigenetic signature.
@ast
Highly efficient derivation of ...... distinct epigenetic signature.
@en
P2093
P2860
P50
P356
P1433
P1476
Highly efficient derivation of ...... distinct epigenetic signature.
@en
P2093
Alyssa K Riley
B Alexander Yi
Hongcang Gu
Huansheng Xu
Ibrahim J Domian
John Lepore
Joo-Hye C Park
Kenneth R Chien
P2860
P2888
P304
P356
10.1038/CR.2011.171
P407
P577
2011-11-08T00:00:00Z